Login / Signup

Evaluating cutaneous lupus disease activity end points and their effects on quality of life as an outcome measure for clinical trials.

M TaraziR G GaffneyR FengV P Werth
Published in: The British journal of dermatology (2019)
Keyphrases
  • disease activity
  • clinical trial
  • systemic lupus erythematosus
  • rheumatoid arthritis
  • rheumatoid arthritis patients
  • ankylosing spondylitis
  • juvenile idiopathic arthritis
  • phase ii
  • open label
  • double blind
  • phase iii